Lundbeck, Solvay discontinue all joint R&D activities for bifeprunox to treat schizophrenia
Monday, August 03, 2009 10:00 IST Valby, Denmark
H Lundbeck A/S (Lundbeck) announced the joint decision with its partner Solvay Pharmaceuticals, B V (Solvay) to stop all joint R&D activities for Solvay's compound bifeprunox in development for maintenance treatment of schizophrenia.